Video
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/YWEGO335JJFB3OWE2UVFL6SUFA.png)
Duración: 01:49
Píldora de Pfizer contra el covid-19 reduciría el riesgo de hospitalización y muerte en casi el 90%
La gigante farmacéutica estadounidense Pfizer realizó una serie de estudios para evaluar la efectividad de su píldora contra la COVID-19 y los resultados son muy esperanzadores. Aquí te contamos más detalles al respecto.
- 15 de diciembre de 2021 04:45 p.m.
- Duración: 01:49
PLAYLIST
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/YWEGO335JJFB3OWE2UVFL6SUFA.png)
Píldora de Pfizer contra el covid-19 reduciría el riesgo de hospitalización y muerte en casi el 90%
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/PFH4CS565NEXVGZFDRPCMNL6OI.png)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/OLNVIHO36RGNBC5OKLVLMA56SI.png)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/2276GOELEJFZRCTCOXLJIXQ7L4.png)
:quality(75)/cdn.jwplayer.com/v2/media/k5ANEfax/poster.jpg)
Lo último en Mundo
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/XGHYCLPQ2FDDFHYNGX4RJ7GVIY.png)
:quality(75)/cdn.jwplayer.com/v2/media/mfbgq6S1/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/hAt46tIH/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/RzRN3okv/poster.jpg)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/EOZQTBZERVADRHLMY2D25TY6DY.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/CWiNeRJW/poster.jpg)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/Q6VI4GFQJNDXHJNIDFZBCXYJCU.png)
:quality(75)/cdn.jwplayer.com/v2/media/1Wzbz1Jr/poster.jpg)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/AEPGO3SP3ZDN7IN5NNVK6PGGB4.png)
:quality(75)/cdn.jwplayer.com/v2/media/EuObDf26/poster.jpg)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/6H46LYZN6ZBJZIJ4K4ZQOWZGTA.png)
:quality(75)/cdn.jwplayer.com/v2/media/4NnkM9Bz/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/PQmoXxDb/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/ZpvMBxDi/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/0f9a2fKn/poster.jpg)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/4WSWKASKIRFMFMX63SX2ZBZPPU.png)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/O23LPBHQIZFG3DSLHKLZIRX2D4.png)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/T3IGNCGW6ZFPJJSBCD7SCP6RWQ.png)
:quality(75)/cdn.jwplayer.com/v2/media/QCjndr6r/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/Ga0PtIGC/poster.jpg)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/GPKZB3R6MFGSZPTKIVB3TELIJI.png)
:quality(75)/cdn.jwplayer.com/v2/media/Eay6KXyw/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/B6wbn2mx/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/blYS7Abv/poster.jpg)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/PFH4CS565NEXVGZFDRPCMNL6OI.png)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/OLNVIHO36RGNBC5OKLVLMA56SI.png)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/2276GOELEJFZRCTCOXLJIXQ7L4.png)
:quality(75)/cdn.jwplayer.com/v2/media/k5ANEfax/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/eyUjAQRO/poster.jpg)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/75LVZYXCEFFQLKF3COQ3FQD4HY.png)
:quality(75)/cdn.jwplayer.com/v2/media/eGTH9X4d/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/THmlA3V0/poster.jpg)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/XX7B77P43FAMFHVHQ3FSCBC2AU.png)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/7T7YBLXP55HTXMTDC5AEWIMXZE.png)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/I5NAJ54Y6BFJHHQHDLZOMSPE7A.png)
:quality(75)/cdn.jwplayer.com/v2/media/BdmYWOaa/poster.jpg)